X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
ChangeDr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
| DR. REDDYS LAB | GLENMARK PHARMA | DR. REDDYS LAB/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 27.3 | 13.9 | 196.7% | View Chart |
| P/BV | x | 2.8 | 3.9 | 72.3% | View Chart |
| Dividend Yield | % | 1.0 | 0.3 | 308.1% |
 DR. REDDYS LAB  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. REDDYS LAB Mar-16 |
GLENMARK PHARMA Mar-16 |
DR. REDDYS LAB/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 4,383 | 1,262 | 347.3% | |
| Low | Rs | 2,750 | 672 | 409.5% | |
| Sales per share (Unadj.) | Rs | 920.1 | 270.6 | 340.1% | |
| Earnings per share (Unadj.) | Rs | 126.1 | 24.9 | 506.9% | |
| Cash flow per share (Unadj.) | Rs | 183.0 | 34.4 | 531.7% | |
| Dividends per share (Unadj.) | Rs | 20.00 | 2.00 | 1,000.0% | |
| Dividend yield (eoy) | % | 0.6 | 0.2 | 271.1% | |
| Book value per share (Unadj.) | Rs | 685.8 | 151.3 | 453.2% | |
| Shares outstanding (eoy) | m | 170.61 | 282.16 | 60.5% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 3.9 | 3.6 | 108.5% | |
| Avg P/E ratio | x | 28.3 | 38.9 | 72.8% | |
| P/CF ratio (eoy) | x | 19.5 | 28.1 | 69.4% | |
| Price / Book Value ratio | x | 5.2 | 6.4 | 81.4% | |
| Dividend payout | % | 15.9 | 8.0 | 197.3% | |
| Avg Mkt Cap | Rs m | 608,481 | 272,778 | 223.1% | |
| No. of employees | `000 | 21.7 | 10.0 | 216.1% | |
| Total wages/salary | Rs m | 31,874 | 13,782 | 231.3% | |
| Avg. sales/employee | Rs Th | 7,244.4 | 7,614.9 | 95.1% | |
| Avg. wages/employee | Rs Th | 1,470.9 | 1,374.8 | 107.0% | |
| Avg. net profit/employee | Rs Th | 992.8 | 700.2 | 141.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 156,978 | 76,340 | 205.6% | |
| Other income | Rs m | 2,693 | 356 | 756.0% | |
| Total revenues | Rs m | 159,671 | 76,696 | 208.2% | |
| Gross profit | Rs m | 34,587 | 14,172 | 244.1% | |
| Depreciation | Rs m | 9,705 | 2,691 | 360.6% | |
| Interest | Rs m | 824 | 1,789 | 46.1% | |
| Profit before tax | Rs m | 26,751 | 10,048 | 266.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,237 | 3,028 | 172.9% | |
| Profit after tax | Rs m | 21,514 | 7,019 | 306.5% | |
| Gross profit margin | % | 22.0 | 18.6 | 118.7% | |
| Effective tax rate | % | 19.6 | 30.1 | 65.0% | |
| Net profit margin | % | 13.7 | 9.2 | 149.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 118,201 | 59,096 | 200.0% | |
| Current liabilities | Rs m | 68,368 | 40,018 | 170.8% | |
| Net working cap to sales | % | 31.7 | 25.0 | 127.0% | |
| Current ratio | x | 1.7 | 1.5 | 117.1% | |
| Inventory Days | Days | 60 | 75 | 80.0% | |
| Debtors Days | Days | 97 | 119 | 81.3% | |
| Net fixed assets | Rs m | 72,265 | 39,075 | 184.9% | |
| Share capital | Rs m | 853 | 282 | 302.3% | |
| "Free" reserves | Rs m | 111,548 | 30,281 | 368.4% | |
| Net worth | Rs m | 117,009 | 42,703 | 274.0% | |
| Long term debt | Rs m | 10,690 | 24,873 | 43.0% | |
| Total assets | Rs m | 200,104 | 111,026 | 180.2% | |
| Interest coverage | x | 33.5 | 6.6 | 505.8% | |
| Debt to equity ratio | x | 0.1 | 0.6 | 15.7% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 114.1% | |
| Return on assets | % | 11.2 | 7.9 | 140.7% | |
| Return on equity | % | 18.4 | 16.4 | 111.9% | |
| Return on capital | % | 21.6 | 17.5 | 123.3% | |
| Exports to sales | % | 46.3 | 43.3 | 106.9% | |
| Imports to sales | % | 9.0 | 7.4 | 120.5% | |
| Exports (fob) | Rs m | 72,618 | 33,044 | 219.8% | |
| Imports (cif) | Rs m | 14,050 | 5,672 | 247.7% | |
| Fx inflow | Rs m | 75,405 | 36,945 | 204.1% | |
| Fx outflow | Rs m | 27,115 | 61,066 | 44.4% | |
| Net fx | Rs m | 48,290 | -24,122 | -200.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 40,476 | 3,449 | 1,173.7% | |
| From Investments | Rs m | -19,421 | -8,802 | 220.7% | |
| From Financial Activity | Rs m | -17,009 | 6,986 | -243.5% | |
| Net Cashflow | Rs m | 4,046 | 934 | 433.3% | |
| Indian Promoters | % | 25.5 | 48.3 | 52.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.4 | 6.9 | 78.3% | |
| FIIs | % | 35.3 | 34.4 | 102.6% | |
| ADR/GDR | % | 18.5 | 0.0 | - | |
| Free float | % | 15.3 | 10.5 | 145.7% | |
| Shareholders | 75,885 | 56,727 | 133.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: WYETH LTD IPCA LABS JUBILANT LIFE SCIENCES AUROBINDO PHARMA PIRAMAL ENTERPRISES
Compare DR. REDDYS LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.
Profits plunge due to higher raw material costs.
Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.
Base price erosion in the US and lower Zetia sales impacts profits.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
More Views on NewsThe data tells us quite a different story from the one the government is trying to project.
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
